Best in Biotech 5 Dec 2024
Five biosimilar companies you should know about
Discover five biosimilar companies creating affordable versions of blockbuster drugs and hoping to capitalize on the upcoming patent cliff.
Biosimilars
- Latest Posts
In Depth 7 Mar 2024
Can AbbVie’s legacy live beyond its once best-selling drug Humira?
The sales of AbbVie’s Humira, once a best-seller, have dropped. Now, with a new CEO announced, things are about to change for the company.
Podcast 9 Feb 2024
Biosimilars and what’s new in cell and gene therapies
This week on the podcast, we have a conversation with Fran Gregory, vice president of Emerging Therapies at Cardinal Health. The discussion covers the company’s role in healthcare, biosimilars, the latest in cell and gene therapies, and Advanced Therapies Week. About Cardinal Health Cardinal Health is a distributor of pharmaceuticals and a global manufacturer and […]
News and Trends 20 Oct 2022
Alvotech and JAMP Pharma add two biosimilar candidates for Canadian market
Alvotech and the JAMP Pharma Group have expanded their exclusive partnership to commercialize biosimilars developed and manufactured by Alvotech. The companies have added two biosimilar candidates from Alvotech’s pipeline: AVT16, a proposed biosimilar to an undisclosed immunology product and AVT33, a proposed biosimilar to an undisclosed oncology product. “We are very pleased to be expanding […]
News and Trends 4 Oct 2022
FDA gives $1.3M grant to Biologics & Biosimilars Collective Intelligence Consortium
The Biologics & Biosimilars Collective Intelligence Consortium (BBCIC) has received a major grant from the Food & Drug Administration (FDA) in support of biosimilars research. The award provides $1.3 million over two years for a new BBCIC study focused on increasing the efficiency of biosimilar drug development and review. The study, “Improving the Efficiency of […]
More News! 17 Oct 2018
The EU Patent of the Best Selling Drug Has Expired, What Does it Mean for Biotech?
AbbVie’s Humira, a treatment for inflammatory disease and the world’s best-selling drug, is no longer patent-protected in the EU. Competitors are already taking advantage of it. Humira is an antibody drug, called adalimumab, that has been topping the lists of best-selling drugs for years. Last year alone, it made over €15B in sales worldwide. The […]
ADVERTISEMENT
ADVERTISEMENT
News and Trends 18 Sep 2017
German Humira Biosimilar for Inflammatory Diseases Cleared for EMA Approval
Cyltezo, an adalimumab biosimilar drug by Boehringer Ingelheim, has received the backing to be marketed in Europe. The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended Cyltezo for approval, moving it closer to the market and offering a new treatment for a range of inflammatory diseases. The biosimilar drug of adalimumab (Humira) could treat […]
News and Trends 28 Aug 2017
Samsung Bioepis Gets European Approval for Biosimilar of Best-Selling Antibody
Samsung Bioepis has announced the European Commission approved Imraldi, a biosimilar of AbbVie’s Humira (adalimumab), which has topped revenue charts for years. Samsung Bioepis’ Imraldi has now marketing authorization in the EU as a biosimilar of Humira (adalimumab) for the treatment of over 10 inflammatory indications, including rheumatoid arthritis, psoriasis, Crohn’s disease and ulcerative colitis. This makes […]
News and Trends 16 Aug 2017
Biosimilars Struggle to Substitute Brand-Name Drugs
Despite bringing a significant price reduction, biosimilars might lag in taking over the market of the drugs they copy because of exclusivity policies set up by the owners of brand-name drugs. A report in Bloomberg Markets yesterday highlights the case of Inflectra, a biosimilar from Pfizer that imitates Johnson & Johnson’s rheumatoid arthritis blockbuster Remicade (infliximab). Despite bringing a price reduction […]
News and Trends 23 Feb 2017
Biosimilars set to take on Oncology after a new Market Authorization
The European Commission has approved Truxima, the world’s first biosimilar monoclonal antibody (mAb) with an oncology indication. Based in South Korea, Celltrion Healthcare is setting foot in the European oncology market with the approval of Truxima, a biosimilar to Roche’s Mabthera (rituximab). The European Commission has approved the antibody for non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis […]
More News! 8 Feb 2017
The FDA lays down Laws of Interchangeability: New Era for Biosimilars?
The new guidelines from the FDA on interchangeability may bring the US biosimilar market up to speed and a new opportunity for European companies. Though the US has long been seen as the most promising market for biosimilars due to the size of the market and high drug prices driving an interest in more affordable options, […]
News and Trends 6 Dec 2016
Sanofi Jumps into the Biosimilars Market aiming for Asia
Sanofi is joining the biosimilars trend to challenge Roche’s best-selling biological with a partnership that aims to take over the Chinese cancer market. Sanofi is going after the €6.8B ($7.3B) that Roche’s Rituxan/MabThera (rituximab), the second top-selling biological, made last year in revenues. The French pharma has signed a deal worth up to €219M ($236M) […]
ADVERTISEMENT
